HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS

被引：0
作者：
Burne, R. [1 ]
Balu, S. [2 ]
Guerin, A. [1 ]
Liang, Y. [1 ]
Schloessmann, R. [3 ]
Bungay, R. [1 ]
Paul, M. L. [2 ]
机构：
[1] Anal Grp Inc, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Chicago, IL USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN120
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
  • [32] Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors
    Antras, Jesus Fuentes
    El Ghamrasni, Samah
    Zou, Jinfeng
    Dou, Aaron
    Elliott, Mitchell J.
    Avery, Lisa
    Bratman, Scott Victor
    Cescon, David W.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [34] Real world incidence and management of adverse events in patients with HR+, HER2-metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting
    Price, Gregory L.
    Sudharshan, Lavanya
    Ryan, Paula
    Rajkumar, Jonathan
    Sheffield, Kristin M.
    Smyth, Emily Nash
    Guimaraes, Claudia Morato
    Rybowski, Sarah
    Carter, Gebra Cuyun
    Gathirua-Mwangi, Wambui Grace
    Huang, Yu-Jing
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (08) : 1319 - 1331
  • [35] The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2-Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered
    Pilehvari, Asal
    You, Wen
    Kimmick, Gretchen
    Camacho, Fabian
    Bonilla, Gloribel
    Anderson, Roger
    CLINICAL DRUG INVESTIGATION, 2025, 45 (02) : 59 - 68
  • [36] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2-metastatic breast cancer treated with a CDK4/6i in the first-line setting
    Behan, Emma
    Veenstra, David L.
    Bansal, Aasthaa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01) : 6 - 14
  • [37] Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2-metastatic breast cancer
    Abu-Khalaf, Maysa M.
    Hatzis, Christos
    Hodge, K. Alex
    Valdes, Frances
    Sikov, William
    Mita, Monica
    Denduluri, Neelima
    Awerkamp, Kris
    Murphy, Rita
    Zelterman, Daniel
    Dunetz, Bryant
    Petricoin, Emanuel
    Pierobon, Mariaelena
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Treatment patterns and barriers involving the use of CDK4/6 inhibitors for women with HR+, HER2-breast cancer.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Ackbarali, Tariqa
    Crawford, Rebecca
    Carter, Jeffrey D.
    Greene, Laurence
    Sapir, Tamar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [39] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
    Prajakta P. Masurkar
    Haluk Damgacioglu
    Ashish A. Deshmukh
    Meghana V. Trivedi
    PharmacoEconomics, 2023, 41 : 709 - 718
  • [40] Composite biomarkers for the prediction of progression-free survival with CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer
    Witkiewicz, Agnieszka
    Wang, Jianxin
    Knudsen, Erik
    Levine, Ellis
    O'Connor, Tracey
    CANCER RESEARCH, 2024, 84 (09)
12345